Interestingly, a study revealed that Nifuroxazide treatment, a signal transducer and activator of transcription 3 (STAT3) inhibitor, was capable of reducing circulating and tumoral MDSC and exerting pro-apoptotic and anti-metastatic activity in the CT26 colorectal cancer mouse model [177]. The gene discussed is STAT3; the disease is colorectal cancer.